Cargando…
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
We report the identification of three structurally diverse compounds – compound 4, GC376, and MAC-5576 – as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for des...
Autores principales: | Iketani, Sho, Forouhar, Farhad, Liu, Hengrui, Hong, Seo Jung, Lin, Fang-Yu, Nair, Manoj S., Zask, Arie, Huang, Yaoxing, Xing, Li, Stockwell, Brent R., Chavez, Alejandro, Ho, David D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418712/ https://www.ncbi.nlm.nih.gov/pubmed/32793898 http://dx.doi.org/10.1101/2020.08.03.235291 |
Ejemplares similares
-
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021) -
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
por: Iketani, Sho, et al.
Publicado: (2021) -
A simplified cell-based assay to identify coronavirus 3CL protease inhibitors
por: Resnick, Samuel J., et al.
Publicado: (2020) -
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
por: Liu, Hengrui, et al.
Publicado: (2022) -
Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites
por: Iketani, Sho, et al.
Publicado: (2022)